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Abstract: Protein lipoxidation is a non-enzymatic post-translational modification that consists of the 
covalent addition of reactive lipid species to proteins. This occurs under basal conditions but in-
creases in situations associated with oxidative stress. Protein targets for lipoxidation include meta-
bolic and signalling enzymes, cytoskeletal proteins, and transcription factors, among others. There 
is strong evidence for the involvement of protein lipoxidation in disease, including atherosclerosis, 
neurodegeneration, and cancer. Nevertheless, the involvement of lipoxidation in cellular regulatory 
mechanisms is less understood. Here we review basic aspects of protein lipoxidation and discuss 
several features that could support its role in cell signalling, including its selectivity, reversibility, 
and possibilities for regulation at the levels of the generation and/or detoxification of reactive lipids. 
Moreover, given the great structural variety of electrophilic lipid species, protein lipoxidation can 
contribute to the generation of multiple structurally and functionally diverse protein species. Fi-
nally, the nature of the lipoxidised proteins and residues provides a frameshift for a complex inter-
play with other post-translational modifications, including redox and redox-regulated modifica-
tions, such as oxidative modifications and phosphorylation, thus strengthening the importance of 
detailed knowledge of this process. 




Lipids constitute a structurally and functionally heterogeneous group of hydropho-
bic biomolecules that, among other species, include fatty acids, triacylglycerols, phospho-
lipids, and sterols. Lipids are essential components of cellular membranes, serve as key 
molecules for the storage of energy, and play important metabolic and signalling func-
tions [1,2]. Lipids can undergo various metabolic transformations, which contribute to 
their great structural and functional variety. Among these reactions, lipid oxidation is a 
common transformation that occurs in physiological conditions as a consequence of cel-
lular metabolism but is usually increased under conditions of oxidative stress, i.e., in sit-
uations where there is a redox imbalance potentially leading to cellular damage. Both en-
zymatic and non-enzymatic mechanisms can be involved in lipid oxidation, and may oc-
cur by radical or non-radical attack [3]. Oxidized lipids play important roles in inflamma-
tion, atherosclerosis, cancer and ageing [4–6]. Importantly, some oxidized lipids are or 
lead to the formation of reactive or electrophilic molecules that can form covalent adducts 
with other macromolecules, including proteins. Electrophilic lipids can also arise from 
dehydration or nitration [7,8]. Thus, the term protein lipoxidation refers to the non-enzy-
matic post-translational modification (PTM) of proteins by reactive or electrophilic lipid 
species, which frequently arise from lipid oxidation. There continues to be some confu-
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sion in the literature between the terms lipid oxidation and lipoxidation, with some re-
searchers erroneously assuming they are synonymous. In addition, it is important to dis-
tinguish both terms from protein lipidation. This process refers to the PTM of proteins by 
lipid moieties, which usually occurs through enzymatic mechanisms, can involve struc-
turally varied lipids, such as glycosylphosphatidylinositol, fatty acids, isoprenoids, and 
cholesterol, and generally affects protein hydrophobicity and localization and/or protein-
membrane or protein-protein interactions [9]. Lipidation can take place at the N- or C-
terminus as well as at cysteine, serine, and lysine residues [9,10]. Moreover, lipids can be 
non-covalently associated with proteins forming complex particles known as lipopro-
teins, which are constituted by a cholesterol-triglyceride core surrounded by phospholip-
ids, other lipids, and embedded proteins [11]. Lipoproteins are essential elements in lipid 
transport and metabolism, as well as in cardiovascular pathophysiology, and both their 
lipid and protein components can undergo various oxidations [12]. In this article, we will 
clarify the terminology (Box 1) and explain the process of protein lipoxidation, before 
addressing advanced aspects of the effects of this PTM and pointing out as yet unan-
swered questions in the field. 
Box 1. Terminology and Definitions. 
 Lipid Oxidation: an overall term encompassing both radical and non-radical (elec-
trophilic) reactions and leading to an increase in the number of oxygens and other 
heteroatoms (such as nitrogen or chlorine) or a decrease in the hydrogen content of 
the lipid. 
 Lipid Peroxidation: a specific form of radical attack, usually at bis-allylic sites in an 
unsaturated hydrocarbon chain, that leads first to a carbon-centred radical and then 
the addition of molecular oxygen to form a peroxyl radical (-O-O•) on that carbon. 
The peroxyl radical remains reactive and can abstract hydrogens from adjacent mol-
ecules, resulting in a chain reaction and propagation of damage. 
 Lipoxidation: covalent reaction of reactive and electrophilic lipid products, mostly 
arising from lipid oxidation, for example, aldehydes or α,β-unsaturated breakdown 
products such as acrolein and 4-hydrononenal, or cyclopentenone-containing lipids 
(e.g., 15-deoxy-Δ12,14-prostaglandin J2) with macromolecules. The targets of lipoxida-
tion include proteins, DNA or head groups of phospholipids. 
 Advanced Lipoxidation End-products (ALEs): the covalent adducts formed by the 
process of lipoxidation. 
 Protein lipoxidation: the modification of proteins by electrophilic lipids. Although 
is not an oxidative modification per se, it frequently contributes to the damage to 
proteins under oxidative stress conditions. 
 Protein lipidation: enzymatically-catalysed covalent modification of proteins by li-
pids, which usually enable the proteins to associate with membranes. Typical exam-
ples include N-myristoylation, S-palmitoylation, or S-prenylation, as well as the ad-
dition of a glycosylphosphatidylinositol anchor. 
 Lipoproteins: particles formed by amphipathic proteins embedded in a phospho-
lipid monolayer and surrounding an inner core of cholesterol, cholesterol esters and 
triacylglycerols. They function as lipid transporters and are commonly found in 
plasma. 
2. Lipid Oxidation and Protein Lipoxidation 
Lipid oxidation can occur enzymatically, catalysed by cyclooxygenases (COX-1/2/3), 
lipoxygenases (LOX), and cytochrome P450-dependent enzymes (CYP450), or non-enzy-
matically, when it is mediated by carbon and oxygen-centred radicals [13,14]. Enzymatic 
pathways give rise to bioactive mediators, such as prostaglandins (PG), thromboxanes 
and leukotrienes, among others, which have been broadly studied and can act as physio-
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logical signalling molecules, with an important role as immunomodulators [15]. Non-en-
zymatic mechanisms are adventitious oxidations that commonly occur on phospholipids 
present in cellular membranes and on lipoproteins [12]. Lipids containing unsaturated 
fatty acyl chains, and particularly those that are polyunsaturated fatty acids (PUFAs), such 
as linoleic and arachidonic acids, are more vulnerable to attack by different reactive spe-
cies of oxygen, nitrogen and halogens [16]. In lipid peroxidation, peroxyl radicals are 
formed as intermediary products [3]. Hence, in a phospholipid bilayer environment, a 
single radical attack can entail a chain reaction based on a cascade of radical hydrogen 
abstractions and oxidations. Peroxyl radicals, and to a lesser extent hydroperoxides, are 
unstable and undergo subsequent reactions including further oxidation, cleavage and cy-
clization reactions to form a variety of secondary oxidation products (reviewed by 
[17,18]). 
Many of these secondary products, including full-chain length oxidized phospholip-
ids, phospholipids with a truncated fatty acyl chain, and non-esterified breakdown prod-
ucts, are reactive electrophilic products that undergo further rearrangements. Both full-
length and shortened fatty acyl chains can contain epoxides, hydroxides, and carboxylic 
acids as well as reactive carbonyl moieties and α,β-unsaturated alkenal moieties, which 
are highly reactive [3,19–21]. In general, alkenals, and hydroxy- or oxo-alkenals are the 
most reactive and versatile in terms of their reactivity [17,22–24]. Certain reactive lipid 
products can be formed by enzymatic and/or non-enzymatic reactions. Dehydration of PG 
synthetised via COX enzymes or non-enzymatically through the isoprostane pathway 
leads to the generation of cyclopentenone prostaglandins (cyPG) or of keto-PG, which 
contain unsaturated carbonyl moieties in the cyclopentenone ring and/or in the lateral 
chains [25–28]. Lipids can also be attacked by reactive nitrogen species (RNS) to give rise 
to nitro-alkenals that also can covalently modify proteins [29]. 
Protein lipoxidation involves the formation of Schiff’s bases or Michael adducts. 
Schiff's bases are formed by the reaction between carbonyls (aldehydes or ketones) and 
primary amines, and consequently can only form on lysine or amino-terminal residues in 
proteins. In contrast, Michael adducts are formed by reaction of a nucleophile with the β-
carbon of an α,β-alkenal, and reactivity is enhanced by the presence of an electron-with-
drawing group on the γ carbon, such as in 4-hydroxynonenal (HNE) or 4-oxononenal 
(ONE). In proteins, the nucleophilic group is most commonly cysteine (in the thiolate 
form), lysine (primary amine in deprotonated form) or histidine (secondary amine in 
deprotonated form). Adducts with asparagine and glutamine side chains have been re-
ported for certain lipid species despite the lower nucleophilicity of the amino group in an 
amide [30]. Arginine can form Michael adducts only when deprotonated, which is rare in 
physiological conditions as the guanidino group is highly basic. This different reactivity 
of protein residues and lipid species influences the selectivity of protein lipoxidation as 
will be discussed below. A summary of the mechanisms is given in Figure 1, while de-
tailed reaction mechanisms for the formation of these adducts and their subsequent rear-
rangements can be found in other reviews [19,31]. Some of the most studied and interest-
ing electrophilic lipids involved in protein lipoxidation are considered briefly below and 
in Table 1. 
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Figure 1. Formation of Schiff’s base and Michael adducts with protein residues. The structures of 
the lysine, cysteine and histidine residues are shown at the top, with the moieties involved in nu-
cleophilic attack indicated. The histidine imidazole ring exists in 2 resonance forms where the hy-
drogen can reside on either nitrogen, so either nitrogen can undertake nucleophilic attack. Schiff’s 
base formation with an amino group is shown in the centre. The Schiff’s base reactions are reversi-
ble, involving a hydrolysis reaction. The bottom panel shows Michael adduct formation by nucleo-
philic group X, where X represents a primary or secondary amine or a thiol. Michael adducts can 
also decompose by reversal of these reactions, although they are more stable than Schiff’s bases. 
Reactive lipid products can be grouped into chemical families according to their re-
active chemical groups, which determine their reactivity in lipoxidation reactions. Owing 
in part to their availability, as well as their biological actions, some reactive lipid products 
have been much more extensively studied than others. The small, non-esterified alde-
hydes malondialdehyde (MDA), acrolein, and HNE fall into this category [23,32]. Of these, 
HNE is the most toxic, acrolein is the most reactive, and MDA is the most mutagenic [33–
35], reviewed in [10,22,36]; these effects ultimately relate to their potential to cause lipox-
idation. In contrast, there are many fewer publications on other aldehydes such as cro-
tonaldehyde, pentanal, hexenal, 4-hydroxy-hexenal (HHE) and 4-hydroxy-dodecadienal, 
although some of them may be formed physiologically in sufficient amounts to have bio-
logical effects and evidence is emerging that they also modify proteins and affect their 
functions. Substantial research has also been devoted to long-chain species, especially iso-
prostanes, isolevuglandins, PG species such as cyPG, and nitrated fatty acids (NO2-FAs), 
in part due to their signalling properties [37–40]. Whereas isoprostanes are important as 
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biomarkers of oxidative stress [41], the behaviour of certain eicosanoids including cyPG, 
and of NO2-FAs as transcription factor agonists and mediators of inflammatory resolution 
has raised high interest in their potential therapeutic applications. Moreover, cyPG have 
been used as model compounds for the identification of lipoxidation targets in proteomic 
studies [27]. Interest in oxidized and nitrated phospholipids as potential agents of lipoxi-
dation is more recent but nevertheless of emerging physiological importance. In sum-
mary, the propensity of a lipoxidation adduct to be formed depends on the reactivity of 
the lipid oxidation product, the nucleophilicity of the target amino acid in the protein, and 
the stability of the product generated [42]. Furthermore, the initial adducts can undergo 
additional rearrangements, including reactions with other nucleophilic groups to cause 
inter- or intra-molecular cross-links, resulting in linear or cyclic stable products [19,43]. 
Thus, protein lipoxidation contributes to the generation of protein diversity through 
PTMs, with a variety of structural and functional consequences. 
Oxidation of lipid components of membranes occurs in all living organisms. There-
fore, the process of protein lipoxidation would be expected to be universal. Indeed, alt-
hough much work has focused on mammalian and clinical samples, protein lipoxidation 
has also been studied in plants and microorganisms. For example, immunoblot analysis 
using monoclonal antibodies against reactive aldehyde-derived protein modifications 
showed that in spinach leaves grown in normal conditions the oxygen-evolving complex 
protein 33 was modified by MDA, acrolein and crotonaldehyde [44], while salt stress in 
Arabidopsis thaliana resulted in modification of soluble proteins by HNE, HHE, crotonalde-
hyde, acrolein and MDA [45]. Excellent reviews that highlight the importance of this PTM 
in plants are available [46,47]. In contrast, little information on natural lipoxidation and 
its effects are available for fungi and bacteria, although it has been reported that bacteri-
cidal antibiotic treatments lead to the formation of MDA adducts [48]. The chemistry and 
generic consequences of lipoxidation on protein function are expected to be similar in all 
of these organisms and will depend on the context and the protein target. However, most 
of the examples provided in this review will be related to animal models in general and 
human health in particular, in relation to the pathophysiological consequences of this 
modification. 
 
Table 1. Examples of electrophilic lipid products that can cause lipoxidation. 









Polyunsaturated chains with 
≥3 double bonds 
Lys (Michael and 




Alkenal (3 carbons) (α-
β-unsaturated alde-
hyde) 
Polyunsaturated lipids but 
also other environmental 
sources 
Lys (Michael and 




Alkenal (4 carbons) (α-
β-unsaturated alde-
hyde) 
ω-3 unsaturated lipids (α-lino-
lenic, eicosapentaenoic or do-
cosahexaenoic acid) 
Lys (Michael and 







ω-3 polyunsaturated lipids (α-
linolenic, eicosapentaenoic or  
docosahexaenoic acid) 
Lys (Michael and 
Schiff’s) 







ω-6 polyunsaturated lipids (γ-
linolenic or 
arachidonic acid) 
Lys (Michael and 
Schiff’s) 
His, Cys (Michael) 
 
√ 






ω-6 polyunsaturated lipids (γ-
linolenic or  
arachidonic acid) 
Lys (Michael and 
Schiff’s) 
His, Cys (Michael) 
√ 
15-deoxy-Δ12,14-prosta-
glandin J2 (15d-PGJ2) 
Cyclopentenone prosta-
glandin (cyPG) 
Arachidonic acid His, Cys (Michael) √ 





ω-6 polyunsaturated lipids (γ-
linolenic or arachidonic acid) 
Lys (Michael and 







ω-6 polyunsaturated lipids (γ-
linolenic or arachidonic acid) 




Arachidonic acid and do-
cosahexenoic acid 






FAs) (can be esterified 
in PLs) 
Unsaturated fatty acyl chains 
(e.g., oleoyl or linoleoyl) 







mitate or stearate attached by 
vinyl ether bond) 
Lys (Schiff’s base only) X 
Diverse electrophilic lipid species from different origins can covalently bind to proteins (protein lipoxidation) through the 
formation of Michael and/or Schiff’s adducts with nucleophilic residues. Some of the reported species can induce protein 
crosslinking. For detailed information, please see [23,24,49–51]. 
3. Functional Consequences of Lipoxidation 
Proteins serve a wide array of functions in the cellular and extracellular contexts, 
which are subjected to complex control, often involving enzymatically generated PTMs, 
such as phosphorylation, glycosylation, ubiquitination, methylation and lipidation, to 
mention just a few. Non-enzymatic modifications of proteins also involve a plethora of 
chemical transformations of protein residues that, especially at high levels, can have del-
eterious effects on protein structure and function. Nevertheless, oxidative and electro-
philic PTMs, including lipoxidation, may also contribute to the regulation of protein func-
tion and play an important role in redox signalling [19,52,53]. Below, the different effects 
of lipoxidation of proteins are considered, together with their potential as physiological 
regulatory processes. Table 2 provides examples of protein targets of lipoxidation and of 
its functional consequences, which are schematically illustrated in Figure 2. 
Lipoxidation of residues located at or near the active site of enzymes can bring about 
changes in enzymatic activity, for example through alterations of their active confor-
mation or by blocking the binding of substrates [54]. Lipoxidation-induced enzyme inac-
tivation has been reported for aldehyde dehydrogenase (ALDH2) [55] and pyruvate ki-
nase [33], and may simply represent damage. In contrast, both activation or inactivation 
have been documented for aldo-ketoreductase B1 (AKR1B1), depending on the size of the 
electrophilic moiety causing the adduct [56,57]. As well as reacting with metabolic en-
zymes, electrophilic lipids can target proteins and enzymes involved in signal transduc-
tion, such as the phosphatases phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase 
(also known as phosphatase and tensin homolog PTEN) and protein phosphatase 2 
(PP2A). PTEN can be modified by acrolein, HNE, prostaglandin A2 (PGA2) or 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2) [58,59], whereas PP2A has been recently reported to be 
modified by HNE [60], resulting in both cases in inhibition, which indirectly affects the 
phosphorylation status of their targets and therefore, their downstream signalling path-
ways. Certain histone deacetylases (HDACs) can also be inhibited by HNE and 15d-PGJ2, 
which affects gene expression [61]. In contrast, activation of metalloprotease-9 by acrolein 
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has been reported [62], with potential implications for tissue damage in a variety of in-
flammatory conditions. 
Electrophilic lipids can also induce protein conformational changes, which may af-
fect activity indirectly, lead to partial unfolding or alter protein-protein interactions. Con-
formational changes often cause changes in secondary structure, such as an unfolding or 
increase in β-sheet content, which tend to favour the formation of amyloid-like structures 
and aggregation of proteins [63]. Examples of specific proteins undergoing these changes 
upon lipoxidation are the ubiquitin hydrolase ubiquitin carboxy-terminal hydrolase L1 
(UCH-L1), which is present in neurofibrillary tangles or Lewy bodies in Parkinson disease 
[64], and glutathione-S-transferase (GST), which is cross-linked in the presence of 15d-
PGJ2 [65]. Moreover, an increased immunoreactivity with anti-ALE antibodies has been 
observed in a number of protein aggregates associated with pathophysiological condi-
tions, including β2-microglobulin amyloid deposits associated with uremic complications 
[66]. This suggests a role for lipoxidation in the pathophysiology of these conditions. Alt-
hough lipoxidation is more likely to affect nucleophilic residues located at the protein 
surface, small aldehydes can gain access into protein folds or binding pockets, leading to 
protein instability and unfolding. This can increase the exposure of hidden residues, ren-
dering the protein more vulnerable to further modification [31]. As a result, the unfolded 
protein response (UPR) may be activated [67–70]. In addition, cross-linking or aggregation 
of proteins prevents their degradation via the 20S proteasome; inhibition of proteasome 
function may then occur, which directly affects cell viability and commonly results in cell 
death [71,72]. 
Table 2. Examples of lipoxidation targets. 





















































































































P53 15d-PGJ2 Cys277 Inhibition [93] 
NF-κB 15d-PGJ2, PGA1 
Cys38 (p65) and Cys62 
(p50) 
Inhibition [94,95] 
STAT3 15-keto-PGE2 Cys259 Inhibition [96] 




15d-PGJ2 Cys227, Cys240 Inhibition [98] 
EGFR HNE ? 
Activation (low lev-
els); inhibition (high 
levels) 
[99] 







Cys151, 273, 288 





















Cys71, Lys327 Inhibition [58,109] 
Akt HNE His196, His267, Cys311 Inhibition [110] 
PP2A HNE ? Inhibition [60] 
Epigenetic regulation 











DRP1 15d-PGJ2 At least Cys644 Fission inhibition [113] 
Cytochrome c HNE His196, His267, Lys87 In vitro modification [114] 
Aconitase HNE 











* ? indicates that either the site of adduction or the biological effect were not determined in this study. 
In some cases, conformational changes induced by binding of electrophilic lipids 
cause protein activation, either through direct or indirect mechanisms. The transcription 
factor peroxisome proliferator-activated receptor γ (PPARγ), which is redox-sensitive 
[90], illustrates this point nicely. Conformational changes in PPARγ during its activation 
trigger heterodimerization with retinoid X receptor, thus promoting the induction of anti-
inflammatory genes and repression of pro-inflammatory genes such as nitric oxide syn-
thase (iNOS) [118,119]. Several electrophilic lipids, including NO2-FAs, oxo-octadecadi-
enoic acid (oxo-ODE) and cyPG cause covalent modification of PPARγ by Michael addi-
tion at the Cys285 residue and promote conformational changes necessary for its full acti-
vation [90–92,120]. Another example is the nuclear factor erythroid 2–related factor 2 
(Nrf2), a transcription factor that is central in the antioxidant response and is indirectly 
activated by lipoxidation. Normally, Nrf2 is bound to its regulator Keap-1, an adaptor for 
ubiquitination that enables Nrf2 proteasomal degradation under non-stressed conditions. 
Modification of critical cysteines in Keap-1 causes a conformational change disrupting the 
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degradation machinery and allowing nuclear translocation of newly synthetized Nrf2 and 
activation of its target genes [121,122]. Therefore, lipoxidation-induced conformational 
changes can also affect protein–protein interactions. The assembly of cytoskeletal proteins 
provides clear examples. Lipoxidation of a single cysteine residue (Cys328) in the inter-
mediate filament protein vimentin can alter filament morphology or cause a complete dis-
ruption of assembly with the formation of aggregates [123]. Similarly, lipoxidation of actin 
at Cys374 can disrupt microfilaments if it occurs in a substantial proportion of molecules 
[80]. Lipoxidation of tubulin alters the morphology of microtubules, inducing a thinner 
appearance [74]. Some of these alterations could be due to steric hindrance caused by the 
addition of bulky moieties. In addition, changes in protein charge due to lipoxidation can 
also affect protein-protein interactions as reported for the binding of lipoxidised albumin 
to the receptor of advanced glycation end products (RAGE) [124]. Finally, lipoxidation 
can alter protein–DNA interactions, as is the case for transcription factor NF-κB, which is 
responsible for the signalling cascade that controls the expression of many proinflamma-
tory genes. Direct lipoxidation of subunit p65 (Cys38) or p50 (Cys62) by 15d-PGJ2 or PGA1 
has been reported to inhibit NF-κB binding to the DNA [94,95], thus reducing expression 
of proinflammatory genes. 
As mentioned above, lipoxidation can influence protein subcellular localization indi-
rectly through changes in protein interactions or degradation. However, the addition of 
electrophilic lipid moieties can also alter membrane targeting, either directly by the action 
of the bound lipid or indirectly if lipoxidation occurs on residues or domains involved in 
subcellular targeting or alters the transport mechanisms. Lipoxidation could increase the 
hydrophobicity of the molecule by altering its charge or introducing acyl groups, which 
could mimic the effects of lipidation and thus influence membrane interaction. The pro-
tein H-Ras poses an interesting example because it can be modified by cyPG at Cys181 
and Cys184 residues [107,108], which are sites of palmitoylation and therefore important 
for subcellular targeting. Indeed, modification of these residues in H-Ras by different moi-
eties has been shown to correlate with its localization to the plasma membrane or endo-
membranes [125]. In turn, lipoxidation of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), although it inactivates the enzyme, induces its translocation to the nucleus 
where it is involved in the induction of apoptosis [62]. Interestingly, lipoxidation of Chro-
mosomal Maintenance 1 (CRM1) inhibits nuclear protein export [126], therefore inducing 
nuclear accumulation of its substrates. 
Although this review is more focused on lipoxidation in the cellular context, protein 
lipoxidation in the extracellular milieu and the bloodstream has important consequences, 
including increased immunogenicity, transfer of proinflammatory and damage signals 
and contribution to a variety of pathophysiological processes [12,127]. In summary, lipox-
idation can impact essential processes including cell signalling and metabolism, cytoskel-
etal function, protein degradation and gene expression. Moreover, regulation of these pro-
cesses by lipoxidation is often double-sided, with either protective or deleterious effects 
depending on the protein target, the nature and the levels of the electrophilic lipid species 
and cellular context factors, which will be discussed below. 
Antioxidants 2021, 10, 295 28 of 28 
 
 
Figure 2. Overview of the biochemical effects of protein lipoxidation, which are highly interrelated. 
 
4. Selectivity and Protein Targets of Lipoxidation 
Investigations of reactive oxidized lipid-protein adducts on entire proteomes have 
shown that not all proteins of a proteome are subject to lipoxidation [75,87,128], thus sug-
gesting that this process is both site-specific and protein selective. Protein lipoxidation 
appears to occur on specific sets of proteins within the cellular proteome, which act as 
“hot spots”. In the circulation, albumin seems to be very susceptible to lipoxidation be-
cause of its abundance and of the high reactivity and accessibility of some nucleophilic 
residues (Cys34 and Lys199) [129]. In the cellular environment, the chaperones Hsp70 and 
Hsp90, Keap1, and the cytoskeletal proteins tubulin, actin and vimentin are frequent tar-
gets of lipoxidation [74,130]. Also, adducts seem to be more common in the cytosol and 
nucleoplasm than in the membrane, although this may depend on the type of lipid and 
on the difficulties to analyse membrane proteins [73,131–133]. In addition, certain cellular 
pathways, such as defence responses, or subcellular localizations appear particularly sus-
ceptible. Studies on the mitochondrial proteome showed that respiratory chain and tricar-
boxylic acid cycle (TCA) proteins, as well as transporters, are the most represented pro-
teins undergoing lipoxidation [134,135]. Codreanu et al. identified HNE and ONE protein 
adducts in THP-1 and RKO cell lines and performed a Gene Ontology (GO) analysis, 
which showed that their function was predominantly involved in folding, RNA metabolic 
and glucose catabolic processes, cytoskeletal regulation and protein synthesis and turno-
ver [136]. This is in agreement with previous studies that identified proteins related to the 
cytoskeleton, stress and immune responses, metabolic processes and glycolysis, regula-
tion of translation and RNA binding as targets for HNE or cyPG in various cellular models 
[74,75,87]. Table 2 gives also examples of the site-specificity of lipoxidation on some target 
proteins, as determined in studies performed mostly in vivo or in cellulo, using physio-
logical or pathophysiological treatment levels of electrophilic lipids and employing mu-
tagenesis approaches to investigate the biological effect. Interestingly, information on sites 
of modification has also been obtained from in vitro studies, which have provided funda-
mental information on relative residue susceptibility and functional consequences, alt-
hough in some cases yielded a higher number of modified residues. Some examples are 
shown in Table 3. 
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Table 3. Multiple modification mapping studies in vitro. 
Protein Targeted Residue (Position) Electrophile Type of Adduction Reference 
Pyruvate kinase 
Cys 49, 152, 326, 358, 423, 474 
Acrolein, HHE 
and MDA 
Michael, Schiff’s or FDP 
adduction 
[33] 
Lys 66, 115, 135, 166, 188, 207, 224, 
247, 270, 305, 367, 393, 475 




HNE Michael [85] Lys 129 
His 60, 71, 161, 268, 283, 295 
Serum Albumin 
Cys 53, 62, 75, 101, 124, 245, 246, 
253, 269, 270, 277, 514 
HNE and MDA 
Michael and Schiff’s (N-
propenal-lysine adduct 
with MDA) 
[137,138] Lys 73, 106, 136, 174, 233, 240, 281, 
378, 525, 541, 545 
His 67, 105, 128, 242, 247, 510 
Apolipoprotein E Lys 64, 67, 68, 135, 138, 149, 155, 254 Acrolein Michael and Schiff’s [139] 
Creatine kinase 
Cys 141, 145, 254, 283 
HNE Michael and Schiff’s [140] 
Lys 86, 101 
His 7, 26, 29, 66, 97, 191, 219, 234, 
276, 296, 305 
Why are some proteins more susceptible to lipoxidation than others? Some of the 
proteins mentioned above (albumin, chaperones, cytoskeletal and glycolytic proteins) are 
highly abundant in cells; as chemical reactions are concentration-dependent, there is a 
higher probability that abundant proteins will be both modified and detected during the 
analysis. However, this is not always the explanation, as illustrated by the lipoxidation of 
transcription factors and signalling proteins, which are minor cellular components. In-
stead, the biochemical characteristics of the protein or enzyme come into play. An im-
portant factor is the reactivity of amino acid sidechains by Schiff’s base formation or Mi-
chael addition, which is determined by their nucleophilicity [24,141]. Generally, the high 
nucleophilicity of the cysteine thiol makes it more reactive than the imidazole in histidine 
or amino group in lysine [134]. This agrees with the observation that out of 398 residue 
sites targeted by HNE in HEK293T cells, most (85.9%) were cysteines (342 residues), and 
only 27 were histidines (6.8%) and 29 lysines (7.3%) [142]. Moreover, in proteins with mul-
tiple cysteine residues frequently only one or two of them are targets for lipoxidation. For 
instance, Cys34 of albumin and Cys374 of actin are the most reactive and commonly mod-
ified residues of these two proteins [129], while the cysteine residues located in the C-
terminal segments of several proteins of the Ras superfamily, including H- and N-Ras and 
Rac1, are lipoxidised [107,143]. This selectivity can arise because of a low pKa of the cys-
teine, which is influenced by its chemical microenvironment; the proximity of basic amino 
acids, such as positively-charged lysines, a metal centre, a catalytic triad or aromatic 
amino acids, lower the pKa and favour the formation of the more nucleophilic thiolate 
form, which is more prone to oxidation and lipoxidation [144–148]. Consequently, those 
thiols can act as redox sensors because they are highly responsive to various oxidative 
modifications. Examples of proteins with unusually low cysteine pKas include protein ty-
rosine phosphatases, thioredoxin (Trx) and peroxiredoxins (Prx). Lysine and histidine 
sidechains are commonly positively charged at physiological pH, but their pKas can also 
be modulated by their local environment through hydrogen bonding and charge stabili-
zation, though as yet this has been less studied. 
Another factor important in determining target residues in a protein is their solvent 
accessibility. A meta-analysis of human proteins identified as targets of HNE and acrolein 
modification showed that adducted residues were, on average, more accessible than the 
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unreactive ones [141]. Similar findings were reported for the modification of pyruvate ki-
nase by 3 small aldehydes [33]. The influence of nucleophilic residue accessibility was 
studied in the context of the modification of mitochondrial proteins by endogenous 2-
alkenals [134], and it was found that local flexibility (B-factor values) and solvent accessi-
bility areas were generally higher on 4 out of 5 cysteine residues that were found adducted 
on mitochondrial malate dehydrogenase. Interestingly, it has been reported that adducted 
residues are surrounded by a greater number of aromatic residues and fewer aliphatic 
residues than unreactive nucleophile residues [141]. 
Clearly, the nature and concentration of the electrophilic lipid species also determine 
the nucleophilic side chains targets in proteins, as explained above [33,42,115] and illus-
trated by the information in Table 2. There is good evidence that size and structure play 
an important role in the selectivity of protein modification. A study on cultured fibroblasts 
found that the closely related cyPG PGA1 and 15d-PGJ2 modified distinct and not totally 
overlapping subsets of proteins, with some targets clearly being preferentially modified 
by one of the cyPG [82,149]. Molecular simulations and docking studies have provided 
insight into the structural basis of the interaction between electrophilic lipids and proteins, 
documenting the basis for selectivity. PGA1 undergoes interactions with residues at the 
active site of AKR1B1 or B10, which favour the formation of a Michael adduct [82]. Simi-
larly, favourable interactions have been proposed for the addition of 15-keto-PGE2 to sig-
nal transducer and activator of transcription 3 (STAT3) [96]. 
Overall, it can be seen that lipoxidation “hot spots” occurring at the level of the pro-
teome and the protein are highly interdependent, and influenced both by the nature of the 
protein, the electrophilic lipid and their concentrations. The situation is further compli-
cated by the fact that other aspects of the cellular environment can influence properties of 
the electrophilic lipids or the adducts, including their availability and stability, thus im-
pacting on the selectivity of the modification. This is considered further in the next sec-
tions and illustrated in Figure 3. 
 
Figure 3. Scheme showing the main factors affecting lipoxidation, from the generation of reactive species and PTM cross-
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5. The Emerging Role of Lipoxidation in Cellular Regulation 
PTMs involved in signalling are generally considered to be fast, reversible and spe-
cific, for these properties provide a high degree of control over the downstream processes. 
As a non-enzymatic modification, the role of protein lipoxidation as a signalling mecha-
nism has been controversial, due in part to an incomplete understanding of the possibili-
ties of regulation of this process. Nevertheless, protein lipoxidation can be modulated at 
several levels, including at the level of generation of the reactive species or their precur-
sors, through their metabolism/detoxification, which influences their availability, or at the 
level of the stability of adducts, which can be regulated by adduct reversal. Some electro-
philic lipids, including cyPG, derive from the dehydration of PG, which in turn are syn-
thesized by regulated enzymatic processes that can be induced under situations of inflam-
mation. Knockout of key enzymes involved in cyPG generation, such as PGD synthase, 
results in a decreased production and action of these electrophilic lipids [150]. Conse-
quently, inhibitors of the phospholipases, COX and/or PG synthases involved in the en-
zymatic steps of PG synthesis may result in a reduction of the generation of the electro-
philic lipids derived from them [151,152]. 
The metabolism or detoxification of reactive lipids or their precursors can be cata-
lysed by diverse enzymes, thus influencing their availability and therefore the extent of 
lipoxidation. GSTs constitute a well-characterized family of enzymes that catalyse the con-
jugation of reduced glutathione (GSH) to electrophilic lipids to generate more soluble spe-
cies that can be exported by multidrug resistance transporters, thus reducing their cellular 
availability [153–156]. Several electrophilic lipids, including cyPG and HNE are substrates 
of GST [153,154,156,157], for which enzymatic and non-enzymatic conjugation GSH has 
been shown to decrease their levels and activity [153,156]. 
Other enzymes that have been proposed as mediators of lipid detoxification include 
soluble epoxide hydrolase (sEH), which can metabolise epoxy fatty acids (PUFAs) [158], 
phospholipid hydroperoxide glutathione peroxidase and the Prxs [29]. A wide and di-
verse group of enzymes can detoxify aldehyde-containing electrophilic lipids. For in-
stance, several isoforms of the aldo-keto reductase (AKR) family use NAD(P)H to reduce 
aldehyde groups of some electrophilic lipids such as acrolein, HNE or cyPG precursors 
[159,160], thus decreasing their availability and biological effects. Other enzymes that can 
reduce the aldehyde group of HNE, including aldose/aldehyde reductase (ALR), alcohol 
dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), alkenal reductase (AER), 
alkenal hydrogenase (ALH), and alkenal/one reductase (ACR) have been reported to re-
duce its bioavailability and reactivity in both plants and humans [32,46]. Thus HNE de-
toxification can occur both by conjugation with GSH or direct detoxification by ADH or 
ALDH [32,161]. Importantly, several enzymes involved in detoxification of electrophilic 
lipids, including GST, AKR and soluble epoxide hydrolase are targets for reactive lipids 
themselves, which increases the complexity of these interactions [65,82,84]. 
A key feature of mechanisms considered to participate in cell signalling is that they 
need to be reversible, either directly or indirectly; lipoxidation shows potential reversibil-
ity through several mechanisms. Although both Schiff’s and Michael adducts are chemi-
cally reversible, Schiff’s adducts are more labile and reversal can occur spontaneously in 
aqueous solution [31], whereas Michael adducts are in general more stable. However, 
retro-Michael reactions are also possible under some circumstances. An adduct formed 
between AKR1B1 enzyme and a biotinylated analogue of PGA1 is partially reversed by 
incubation in the presence of an excess GSH in vitro [162]. Furthermore, Michael adducts 
generated by HNE and ONE can be reverted in vitro and in cells as demonstrated by 
quantitative chemoproteomic analysis [163] and kinetic studies [164]. In cells, the involve-
ment of enzymatic mechanisms in the reversal of lipoxidation has been proposed. Acro-
lein protein adducts are reversed in bronchiolar epithelial cells by mechanisms dependent 
on GSH and Trx 1 [165]. In addition, the deacetylase Sirt2 has been reported to catalyse 
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the enzymatic reversion of acrolein lipid adducts [166,167], as revealed by quantitative 
analysis [163]. NO2-FAs are a special case, since their adducts with cysteine residues are 
reversible, and there is consensus that they can behave as signalling mediators [168,169], 
although there is still much to be learned about the potential regulation of their generation 
and site of action. 
The functional reversal of lipoxidation can also be achieved indirectly by degradation 
of the lipoxidised proteins and substitution by newly synthesized proteins with the con-
sequence of the recovery of the biological effect [50,170]. As stated above, lipoxidation is 
frequently associated with inhibition of proteasomal degradation. Therefore, removal of 
protein-lipid adducts has been proposed to occur through lysosomal degradation and au-
tophagy [171], especially of those containing α,β-unsaturated carbonyl groups or alde-
hydes. 
Specificity is an important aspect of regulatory processes. Besides the selective as-
pects of lipoxidation discussed above, several lines of evidence indicate that in some cases 
protein lipoxidation can display distinct structure-function relationships. Lipoxidation of 
members of the AKR family by different species can lead to distinct functional conse-
quences. Whereas modification by small moieties such as acrolein at Cys298 of AKR1B1 
increases its catalytic activity [56], the addition of bigger reactive lipids such as HNE or 
certain cyPG promotes the inactivation of these enzymes [57,162]. The assembly of cyto-
skeletal protein vimentin is also sensitive to modulation by lipoxidation of its single cys-
teine residue and displays differential features depending on the structure of the adducted 
lipid [123]. However, whether this is a physiological mechanism of signalling is not 
known at present. 
6. The Dependence of Lipoxidation on the Cellular Environment 
Reactive lipids can exert both beneficial and detrimental effects on the cell [38]. 
Which of these predominates depends on many factors that influence the generation and 
final fate of the lipids and their adducts, including the cell type, the status of the antioxi-
dant defences, and the concurrence of other reactive species or stimuli. The complexity of 
this balance is illustrated by the fact that electrophilic lipids can induce the expression of 
antioxidant defence enzymes, but at the same time influence their activity either directly, 
through lipoxidation, or indirectly, by triggering the production of reactive oxygen spe-
cies (ROS) (see [172] for review). 
The antioxidant system of the cell includes both enzymatic and non-enzymatic ele-
ments. Enzymes contributing to the antioxidant defence include the superoxide dismutase 
(SOD), heme oxygenase-1 (HO-1), catalases, glutathione peroxidase, Prxs, glutathione re-
ductases and Trx. Small-molecule antioxidants include GSH, vitamins, lipoic acid and sev-
eral cations such as Mn, Fe, Cu or Zn [63,173]. An example of the interplay between these 
factors and lipoxidation is provided by the cell- and species-dependent subcellular com-
partmentalization of cyPG accumulation and effects. For instance, differences in the main 
site of inhibition of the NF-κB activation pathway (through either cytoplasmic or nuclear 
events) have been attributed to the distinct subcellular distribution and abundance of an-
tioxidant defences, i.e., GST activity and GSH content, in different cell types (see [172] for 
review). Therefore, increased levels of GSH, or enzymes involved in cyPG metabolism 
such as GST, are associated with lower levels of cyPG modification, and vice versa. More-
over, the stability of the adducts between electrophilic lipids and GSH depends on the 
lipid species [174], for which GSH levels will not affect the availability of electrophilic 
lipids uniformly. In addition, the observation that non-hydrolysable GSH analogues pro-
tect certain proteins, e.g., GSTp, from lipoxidation suggests the involvement of steric ef-
fects or induction of conformational changes in the protective effects of GSH [65]. Finally, 
these elements are dynamic, which increases the complexity of these interactions. For in-
stance, cytosolic GSTs can translocate to the nucleus, altering the location of protection 
[175,176]. 
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The complexity of these interactions is even higher since electrophilic lipids also in-
fluence the activity of the detoxifying enzymes. Certain electrophilic lipids can bind and 
inactivate GST and/or induce its crosslinking [65,177]. In addition, the reduced form of 
Prx is a direct target of HNE [178] whereas Trx can be modified by acrolein and HNE at 
the non-catalytic Cys73 [179] and by cyPG at Cys35 and Cys69 [180]. Moreover, TrxR is 
also a target for lipoxidation [181]. In most cases, lipoxidation is associated with inhibition 
of these targets, thus inducing the accumulation of cellular ROS. Nevertheless, as stated 
above, interaction with GSH can protect these enzymes from lipoxidation. 
Vitamins may act as both pro- and anti-oxidants and their interactions with electro-
philic lipids and lipoxidation appear to be complex and dependent on the experimental 
system. Examples of these interactions include reports on vitamin E decreasing lipid pe-
roxidation in clinical trials or studies [182] and the ability of vitamin B6 to sequester inter-
mediates of lipid peroxidation and reduce the formation of lipoxidation adducts [183,184]. 
Nevertheless, some actions of vitamins are controversial and the reader is referred to spe-
cialized reviews on this topic [170,173,185]. 
Divalent cations such as iron, copper, zinc or manganese also influence the redox 
state of the cell through various mechanisms including radical generation through the 
Fenton reaction (iron and copper), radical scavenging (manganese) or acting as cofactors 
for antioxidant enzymes (reviewed in [173]). In the context of lipoxidation, zinc presents 
special interest. Zinc competes with iron and copper in their coordination environments 
and suppresses their redox activity in Fenton chemistry. Interestingly, Zn2+ can interact 
with the thiolate group of cysteine, with important implications in Redox Biol, and the 
imidazole group of histidine [186], both of which are strong nucleophiles and frequent 
targets of lipoxidation. Zinc binding can affect the reactivity of cysteine residues and/or 
protect them from chemical modification, including lipoxidation [187,188]. The cytoskel-
etal protein vimentin provides an example of this protection both in vitro and in cells, 
since zinc availability in the physiological range protects the single cysteine residue of 
vimentin from alkylation, oxidation or lipoxidation in vitro, and preserves the integrity of 
the network in cells [188]. In turn, oxidation or lipoxidation of cysteine residues involved 
in the interaction with zinc releases this metal and contributes to zinc toxicity in cells [189]. 
On the other hand, metal-ion chelators inhibit lipoxidation reactions through the elimina-
tion of metal ions [170]. Some examples of compounds which can act as metal-ion chela-
tors include citric acid (relatively non-specific chelator) [170], polyphenols and flavonoids 
[173]. 
Among other factors related to the cellular or extracellular context that can modulate 
lipoxidation is the presence of scavengers or quenchers. While the two terms are often 
used interchangeably, scavengers could be considered non-covalent binders of electro-
philic lipids, whereas quenchers would be strong nucleophilic compounds reacting with 
the electrophilic derivatives leading to unreactive products. Thus, scavenging or quench-
ing of electrophilic lipids could prevent protein lipoxidation. Therefore, in addition to en-
dogenous compounds entailing this activity, exogenous natural and synthetic quenchers 
are being studied as potential therapeutic tools [170,190]. One of the best-studied exam-
ples is the dipeptide carnosine composed of β-alanine and histidine, which has served as 
the basis for the synthesis of more stable analogues, one which, known as carnosinol, has 
been found to decrease lipoxidation and showed beneficial effects in animal models of 
disease [191]. 
Finally, the presence of other reactive species, either endogenous or exogenous, such 
as drugs and their metabolites can influence lipoxidation by causing alterations in the cel-
lular antioxidant systems or the protein targets, and even compete for target residues con-
tributing to PTMs crosstalk. Therefore, factors from the cellular context may influence the 
extent and the site of protein lipoxidation, contributing to its selectivity and accounting 
for potential differences in the results from in vitro and in in vivo studies. 
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7. Interplay among Post-Translational Modifications 
Lipoxidation can induce oxidative stress, thus eliciting the formation of further reac-
tive species, responsible for additional PTMs leading to chain reactions with implications 
in different cellular processes [192]. Moreover, lipoxidation of enzymes involved in PTMs, 
such as phosphatases, kinases or deacetylases (see above), can affect PTMs. Therefore, a 
complex interplay between PTMs can take place involving lipoxidation, modifications by 
other reactive species, and activation or inhibition of proteins catalysing other PTMs. 
Moreover, direct cooperation or competition among PTMs can occur on the same proteins 
or residues, which could result in an increase of protection from lipoxidation, thus con-
tributing to the generation of highly diverse proteoforms and the complexity of events 
determining the overall outcome. 
Among reactive species potentially competing with electrophilic lipids for modifica-
tion of proteins are species derived from the oxidation of sugars, ROS and RNS and other 
small molecules, like metabolites of certain amino acids, or even drugs. The modification 
of cysteine residues can provide numerous examples of this potential competition, given 
their capacity to accommodate multiple modifications [193,194]. In general, it could be 
considered that cysteine oxidation in its various forms, including formation of disulphide 
bonds, sulfenic and sulfonic acids, nitrosation, etc., would make the residue less available 
for lipoxidation. Nevertheless, sulfenic acids have been reported to be more reactive to-
wards certain electrophilic compounds [195], while some disulfides are highly reactive 
with oxidants [196]. Therefore, in certain cases, cysteine reversible modifications, includ-
ing disulphide formation, glutathionylation, nitrosation, or addition of NO2-FAs, could 
confer protection against more deleterious ones involving the formation of stable adducts, 
protein crosslinks, unfolding or aggregation [197,198]. 
Several previously discussed lipoxidation targets provide examples of these protec-
tive mechanisms. The enzyme AKR1B1 possesses seven cysteine residues, two of which, 
Cys298 and 303, are close to the active site. Formation of a disulphide bond between these 
cysteine residues reversibly inactivates the enzyme. Nevertheless, this modification could 
prevent a more stable modification causing either activation or inactivation of the enzyme. 
For instance, the cyPG PGA1 forms an adduct with Cys298 resulting in inhibition. The 
single cysteine residue of vimentin, Cys328 can also be the target for a wide variety of 
modifications. Reversible modifications of this residue include disulphide formation, ni-
trosation or glutathionylation, which can have different functional consequences [199]. 
Nitrosation, in particular, appears to elicit only minor alterations of vimentin assembly in 
vitro [200]. Therefore, it would be interesting to explore whether this reversible modifica-
tion can play a protective role against more disruptive modifications such as CyPG addi-
tion. Interestingly, in vitro incubation of vimentin or a PPARγ construct with the nitrated 
phospholipid 1-palmitoyl-2-oleyl-phosphatidylcholine (NO2-POPC) shields their cysteine 
residues from alkylation [201]. Whether this is due to the occurrence of competing modi-
fications requires further study. 
Lipoxidation maintains an important interplay with phosphorylation through vari-
ous mechanisms. As briefly discussed above, several kinases and phosphatases contain 
reactive thiols that are subjected to redox control and can be targets for several electro-
philic species. Examples of kinases with reactive thiols include protein kinase A (PKA), 
PKG, PKC and Ca2+/calmodulin-dependent protein kinase II (CaMKII) [202,203]. Moreo-
ver, both 5′ AMP-activated kinase and AKT have been shown to be direct targets for lipox-
idation by HNE [110,204]. Moreover, kinase cascades can be indirectly activated by lipox-
idation. Monomeric GST binds and sequesters several stress kinases such as c-Jun N-ter-
minal kinase (JNK) or Traf-2 or binds to their substrates [205,206] in such a way that oxi-
dation or lipoxidation-induced GST crosslinking results in the activation of the corre-
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sponding stress signalling pathways [65,205,207]. In turn, lipoxidation of Ras proteins elic-
its their activation and that of downstream kinase cascades, including MAPKs, phospho-
inositide 3-kinase (PI3K) and AKT [107,208]. 
In addition, several serine and tyrosine phosphatases can be regulated by redox 
mechanisms and are targets for lipoxidation, which can result in activation or inactivation 
of phosphatase activity, generally leading to reciprocal changes in the phosphorylation 
level of its substrates and modulation of the corresponding pathways [209]. Examples of 
phosphatases subjected to this control are PP2B, PP1, PP2A and PTEN. Lipoxidation of 
PP2A by PGA1 through the formation with a Michael adduct at Cys377 reduces the phos-
phorylation state of Tau [210]. In contrast, several electrophilic lipids, including acrolein, 
HNE and cyPG covalent modify and inactivate PTEN, resulting in activation of the AKT 
pathway and increased proliferation in several cancer cell lines [58,59]. Recently, the for-
mation of an adduct of 15d-PGJ2 with Cys136 of PTEN has been reported [211]. Im-
portantly, the possibility that electrophilic lipids can alter the expression levels of kinases 
or phosphatases provides an additional layer for interplay [212]. Therefore, alterations in 
protein phosphorylation status could be commonly associated with lipoxidation, and the 
occurrence of both modifications on the same target would influence the final outcome. 
For instance, in the case of vimentin, lipoxidation and phosphorylation appear to cooper-
ate to induce filament disassembly [123]. However, in the case AKT, HNE indirectly pro-
motes its phosphorylation, which would normally lead to activation but at the same time, 
directly modifies the enzyme, resulting in inhibition [110]. 
Importantly, direct competition between lipoxidation and phosphorylation could oc-
cur at histidine residues, which can be targets for both kinds of modification [213], alt-
hough this potential interplay, to the best of our knowledge, has not been explored in 
detail. Other unusually phosphorylated amino acids include lysine and arginine. 
Lipoxidation can also affect protein acetylation. Several HDACs are targets for lipox-
idation. Indeed, a feedback mechanism controlling the expression of stress genes has been 
proposed that depends on the modification of certain HDACs by cyPG and HNE [61]. 
Moreover, lipoxidation of Sirt3 by HNE associates with mitochondrial protein hyper-
acetylation [214]. Notably, as lysine residues are targets for both lipoxidation and acetyla-
tion, the interplay between both modifications could occur also at this level. Similar inter-
actions that could affect other modifications such as lysine ubiquitination or formylation 
deserve investigation. 
8. Conclusions 
In summary, modification of proteins by lipoxidation can elicit varied functional con-
sequences and affect a myriad of intracellular processes. Being a non-enzymatic modifi-
cation, envisaging potential regulatory roles of lipoxidation is controversial. The chain 
reaction provoked by lipid oxidation could expand in a flood-like manner affecting mul-
tiple proteins and pathways. Nevertheless, accumulating evidence indicates that protein 
lipoxidation is not a random process, which could be subjected to regulation at several 
levels. Indeed, low or moderate level protein lipoxidation appears to be involved in cellu-
lar defence responses and adaptation to stress. Currently, it is not clear how cells could 
harness this process in physiological situations. However, the interplay with generation 
of antioxidant defences, such as GSH, with detoxifying and repairing enzymes, and with 
other PTMs are unveiling further possibilities for modulation of the effects of lipoxidation. 
Detailed knowledge of these processes will be necessary to understand its involvement in 
pathophysiology as well as the possibilities for therapeutic intervention. 
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Abbreviations 
ACR Alkenal/one reductase 
ADH Alcohol dehydrogenase 
AER Alkenal reductase 
AKR Aldo-keto reductase 
AKR1B1 Aldo-ketoreductase B1 
ALDH Aldehyde dehydrogenase 
ALDH2 Aldehyde dehydrogenase 2 
ALEs Advanced lipoxidation end products 
ALH Alkenal hydrogenase 
ALR Aldose/aldehyde reductase 
CaMKII Ca2+/calmodulin-dependent protein kinase II 
COX Cyclooxygenases 
CRM1 Chromosomal maintenance 1 
cyPG Cyclopentenone prostaglandin(s) 
CYP450 Cytochrome P450 
FDP Nε-(3-formyl-3,4-dehydropiperidino) 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFAP Glial fibrillary acidic protein 
GO Gene ontology 
GSH Reduced glutathione 
GST Glutathione S-transferase 
HDACs Histone deacetylases 
HNE 4-hydroxynonenal 
Hsp70 Heat shock protein 70 
Hsp90 Heat shock protein 90 
iNOS Nitric oxide synthase 
LOX Lipoxygenases 
MDA Malondialdehyde 
NF-κB Nuclear factor-κB 




Nrf2 Nuclear factor erythroid 2–related factor 2 
ONE 4-oxononenal 
oxo-ODE Oxooctadecadienoic acid 
PG Prostaglandin(s) 
PGA1 Prostaglandin A1 
PGA2 Prostaglandin A2 
PGD Prostaglandin D 
PGE2 Prostaglandin E2 
PI3K Phosphoinositide 3-kinase 
PKA Protein kinase A 
PKC Protein kinase C 
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PKG Protein kinase G 
PP1 Protein phosphatase 1 
PP2A Protein phosphatase 2 
PP2B Protein phosphatase 2B 





PTM Post-translational modification 
PUFAs Polyunsaturated fatty acids 
RAGE Receptor of advanced glycation end products 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
sEH soluble epoxide hydrolase 
SOD Superoxide dismutase 
STAT3 Signal transducer and activator of transcription 3 
TCA Tricarboxylic acid cycle 
Trx Thioredoxins 
UPR Unfolded protein response 
15d-PGJ2 15-deoxy-Δ12,14-prostaglandin J2 
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